I did a search on pubmed and it shows over 4800 entries where FTO is discussed in papers
The graph below shows the growth in FTO research, which appears to start in 2007.
The last 3 tall bars are figures over 500pa
In 2024 we are at 265 papers.
Given what Su et al found in 2020, which was totally independent to Race, suggests any BP playing in this space would know about FTO.
In my opinion the bigger driver to a commercial outcome for Race will be patent cliffs and sustaining BP revenue opportunities once Bisantrene is proven to have CPACS and efficacy with their existing oncology drug. At that point they will have to learn/know FTO.
Speculative M&A Transaction Analysis, page-718
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |